MedTrace Logo

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

NCT02737475 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2022-01-25

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.

Conditions

Interventions

DRUG

BMS-986178

Specified dose on specified days

DRUG

Nivolumab

Specified dose on specified days

DRUG

Ipilimumab

Specified dose on specified days

BIOLOGICAL

Tetanus vaccine

Specified dose on specified days

BIOLOGICAL

DPV-001 vaccine

DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days

DRUG

Cyclophosphamide

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-17
Primary Completion
2020-11-02
Completion
2020-11-02
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Israel
  • Italy
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02737475 on ClinicalTrials.gov